Characteristics | Unadjusted OR (95% CI) | Model I | Model II | Model III | |||
---|---|---|---|---|---|---|---|
Adjusted OR (95% CI) | Attributable risk | Adjusted OR (95% CI) | Attributable risk | Adjusted OR (95% CI) | Attributable risk | ||
Age ≥ 70 | 1.01 (0.61–1.66) | ||||||
Diabetes mellitus | 1.70 (1.03–2.78)* | ||||||
Duration ≥12 weeks | 2.31 (1.40–3.82)** | 1.79 (0.99–3.24) | 1.81 (1.05–3.14)* | 44.9 | 1.80 (1.05–3.08)* | 44.3 | |
Benzodiazepine | 1.93 (1.15–3.25)* | ||||||
GABA analogue | 4.39 (2.53–7.60)*** | 2.80 (1.42–5.54)** | 64.3 | 4.55 (2.57–8.05)*** | 78.0 | 2.98 (1.66–5.33)*** | 66.4 |
Oxycodonea | 8.20 (3.06–21.97)*** | 5.73 (2.08–15.77)*** | 82.6 | ||||
Morphinea | 13.75 (5.03–37.61)*** | 7.53 (2.60–21.86)*** | 86.7 | ||||
Combination therapy | 2.35 (1.13–4.91)* | 2.39 (1.03–5.53)* | 58.1 | ||||
MME ≥ 60 | 6.75 (3.23–14.12)*** | 4.17 (1.92–9.04)*** | 76.0 |